Magnesium

Nutrient versus ergogenic aid

Magnesium has essential physiological roles. That does not establish extra performance benefit when intake is adequate. AIS currently places magnesium in Group C for sports supplementation.

Evidence

Use or skip

Review diet and a specific clinical concern first. A deficiency-related need differs from routine supplementation; cramps alone are not a diagnosis. Most adequately nourished runners need no performance-focused magnesium product.

Evidence

Dose and timing

No validated ultra-performance dose or pre-race timing is established here. Deficiency treatment is individualized by a clinician, not a chronic or acute race protocol.

Evidence

Risks and subgroups

Supplements may cause diarrhea; impaired kidney function increases toxicity risk. Some antibiotics and osteoporosis medicines interact. Older adults can have higher inadequacy risk, which does not prove an ergogenic benefit. No women-specific ultra advantage is established.

Evidence

Product and value

Check elemental magnesium rather than compound weight. Batch purity and competition rules remain separate checks. A premium form or sleep claim does not establish ultra usefulness.

Evidence

Separate three different questions

First ask whether your usual diet plausibly meets your needs. Second ask whether a health condition or medicine warrants professional assessment. Third ask whether extra magnesium improves a chosen running outcome when nutritional status is already adequate. These are different questions; a convincing answer to the first or second does not automatically make a sports-performance claim true.

Make a simple list of foods, supplements and relevant medicines before a professional discussion. Include combination electrolyte products because the same mineral may appear in several places. Do not treat the number of products as evidence of nutritional adequacy. If a product lists a compound amount, look for the declared elemental magnesium amount rather than assuming they are equivalent.

For a runner whose only concern is a marketing promise about recovery, cramps or sleep, ask what direct evidence supports that particular claim in comparable athletes. A testimonial or a plausible role in muscle function is insufficient. If no relevant benefit is established and there is no assessed nutritional need, skipping the purchase is reasonable. This is not a recommendation to ignore persistent symptoms; symptoms should be assessed on their own merits rather than assigned to a deficiency by an advertisement.

What follow-up can and cannot tell you

If a clinician recommends supplementation for a nutritional or medical reason, agree on the purpose, duration and follow-up with that clinician. Do not replace that plan with a race-day experiment or alter prescribed medicine timing yourself. Keep a note of tolerance and all products used so the professional can interpret any problems.

A change in sleep, soreness or cramping during a busy training period has multiple possible explanations. It cannot establish that magnesium improved performance or that a deficiency existed. Equally, an older runner's increased risk of inadequate intake does not create an automatic dose for all older runners. Keep the decision tied to an assessed need, not age, sex or event distance alone. This avoids both unnecessary spending and false reassurance.

Make the decision reviewable

Write down the reason for your decision, the uncertainty that remains and when you will revisit it. New symptoms, a different training goal or stronger relevant research can change the decision; a new advertisement alone need not.

Use this with

• Protein for endurance adaptation
• Daily energy and training nutrition
• Fuel Protocol
• Recovery Protocol

Evidence and limits

Evidence: Limited. Sport-level assessment; ultra-specific benefit unestablished. Does not deny physiological importance or clinician-led deficiency treatment.

• AIS Group C (opens in a new tab) · Appraisal and population
• NIH ODS: Magnesium (opens in a new tab) · Appraisal and population
• USADA: How to Reduce Your Risk from Supplements (opens in a new tab) · Appraisal and population

Editorial method · Report a correction